Shares of Mylan (MYL) - Get Free Reportwere higher Tuesday after a U.S. District Court rejected competitor Teva Pharmaceuticals' (TEVA) - Get Free Report claims of patent infringement on a drug used to treat multiple sclerosis. This opens the door for Mylan which has been working on a more affordable, generic version of the drug. This comes as embattled EpiPen-maker said it was under investigation by the Federal Trade Commission for violation of antitrust laws. However, the company released a statement saying, "Mylan received an information request from the FTC months ago as part of a preliminary investigation. Any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit."
CATEGORIESTechRetailCryptoFinanceMarketsInvestingEconomicsEntertainmentPersonal FinanceBreaking NewsVideoTheStreet DealsNewsletters
PREMIUM PRODUCTSTheStreet SmartsAction Alert PlusReal MoneyCrypto InvestorReal Money ProQuant RatingsRetirement DailyTop StocksCompare All